Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: John A. Stoops who wrote (1160)	3/15/1999 7:39:00 PM
From: William Partmann	Read Replies (3) \| Respond to of 1580

Merck's Mevacor wins FDA ok for expanded use WEST POINT, Pa., March 15 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Merck & Co.'s (NYSE:MRK - news) cholesterol-lowering medicine Mevacor to help lower the risk of a first heart attack. Based on results of a study, Mevacor is now indicated to reduce the risk of first heart attack, unstable angina and coronary ''revascularization'' procedures, the release said.